What is Damora Therapeutics, Inc.?
, a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.44B, and a P/E ratio of 13.6x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 112,500 shares $253k |
| 3-6months | 1245 shares $7k | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 31,090 shares $23k | 0 |